Adaptimmune reports positive results for multiple myeloma T-cell trial
This article was originally published in Scrip
Executive Summary
UK-headquartered biotechnology firm Adaptimmune has reported encouraging early stage results for its T-cell receptor (TCR) technology in multiple myeloma – highlighting promising response rates, safety and proof of mechanism.